2015: Which new directions for Alzheimer's disease?

According to the World Health Organization, more than 40 million people in the world are affected with dementia. To date, 60-70% of the cases of dementia are attributed to the Alzheimer's disease (AD). This neurodegenerative disorder gradually takes place over a period of at least 20 years befo...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autor: Ludovic Martin (auth)
Médium: Kapitola
Vydáno: Frontiers Media SA 2015
Témata:
On-line přístup:Get Fullteks
DOAB: description of the publication
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
LEADER 02991naaaa2200313uu 4500
001 doab_20_500_12854_39880
005 20210211
020 |a 978-2-88919-535-0 
020 |a 9782889195350 
024 7 |a 10.3389/978-2-88919-535-0  |c doi 
041 0 |a English 
042 |a dc 
100 1 |a Ludovic Martin  |4 auth 
245 1 0 |a 2015: Which new directions for Alzheimer's disease? 
260 |b Frontiers Media SA  |c 2015 
300 |a 1 electronic resource (122 p.) 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a According to the World Health Organization, more than 40 million people in the world are affected with dementia. To date, 60-70% of the cases of dementia are attributed to the Alzheimer's disease (AD). This neurodegenerative disorder gradually takes place over a period of at least 20 years before the onset of symptoms, which are impaired memory, apathy and depression. The characteristics of AD consist in neurofibrillary tangles (intraneuronal aggregates of hyperphosphorylated tau proteins) and senile plaques (dense extraneuronal deposits composed of amyloid ß (Aß)). The other features linked to these two core pathological hallmarks of AD are inflammation, oxidative stress, progressive synaptic and neuronal loss. In past years, some of the emerging therapeutic strategies against AD were employed to deal with the pathological hallmarks of the disease. Science teams all over the world try to restore the tau phosphorylation equilibrium. Their purpose is to interfere with the aggregation of tau and decrease its amount of proteins per se as well. Furthermore, they are trying either to stimulate the elimination processes of the aggregated tau proteins or to stop the formation of Aß peptides. This could be reached by the stimulation of the classic techniques of protein degradation such as the autophagic pathway, or by the targeted immunotherapy. In this Research Topic, we wish to summarize and review the etiology of AD and the related therapeutic opportunities for the next decades. To fully understand the precise mechanisms underlying AD, research findings, reviews, new insights and new approaches include AD and related tauopathies, tau phosphorylation balance, pharmacological compounds against AD, neuroprotection strategies and new therapeutic ways but also risk factors for AD and AD genetic information are included in this issue. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
653 |a kinase inhibitors 
653 |a Therapeutics 
653 |a tau 
653 |a TREM2 
653 |a Alzheimers disease 
653 |a microbiome 
653 |a Aβ peptides 
856 4 0 |a www.oapen.org  |u http://journal.frontiersin.org/researchtopic/1283/2014-what-new-directions-for-alzheimers-disease  |7 0  |z Get Fullteks 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/39880  |7 0  |z DOAB: description of the publication